Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
Updated: 1/1/1970
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
James Graham Brown Cancer Center
mi
from
Louisville, KY
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
Updated: 1/1/1970
James Graham Brown Cancer Center
mi
from
Louisville, KY
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
Phase I Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Status: Archived
Henry Ford Hospital
mi
from
Detroit, MI
Phase I Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
mi
from
Detroit, MI
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Status: Archived
Ohio State University
mi
from
Columbus, OH
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients
A Randomized, Intent to Treat, Controlled Study of the Efficacy of Verum Acupuncture Compared to Sham Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Subjects That Have Undergone Axillary Surgery
Status: Archived
Legacy Emanuel Hospital and Health Center and Children's Hospital
mi
from
Portland, OR
Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients
A Randomized, Intent to Treat, Controlled Study of the Efficacy of Verum Acupuncture Compared to Sham Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Subjects That Have Undergone Axillary Surgery
Status: Archived
Updated: 1/1/1970
Legacy Emanuel Hospital and Health Center and Children's Hospital
mi
from
Portland, OR
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Methylphenidate and a Nursing Telephone Intervention for Fatigue
A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Methylphenidate and a Nursing Telephone Intervention for Fatigue
A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Methylphenidate and a Nursing Telephone Intervention for Fatigue
A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients
Status: Archived
Lyndon B Johnson Hospital
mi
from
Houston, TX
Methylphenidate and a Nursing Telephone Intervention for Fatigue
A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients
Status: Archived
Updated: 1/1/1970
Lyndon B Johnson Hospital
mi
from
Houston, TX
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
McFarland Clinic, PC
mi
from
Ames, IA
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
mi
from
Ames, IA
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
GSK Investigational Site
mi
from
Chesterfield, MO
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Chesterfield, MO
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
See Detailed Description
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
A Phase II Trial of Cetuximab, Gemcitabine, 5-Fuorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma
Status: Archived
Umass Memorial Medical Center
mi
from
Worcester, MA
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
A Phase II Trial of Cetuximab, Gemcitabine, 5-Fuorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
mi
from
Worcester, MA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Norwalk Hospital
mi
from
Norwalk, CT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Norwalk Hospital
mi
from
Norwalk, CT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Virginia Cancer Center
mi
from
Richmond, VA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Virginia Cancer Center
mi
from
Richmond, VA
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
Pilot Study of Viral Load and Transcription in Kaposi's Sarcoma Patients Treated With Liposomal Anthracyclines
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
Pilot Study of Viral Load and Transcription in Kaposi's Sarcoma Patients Treated With Liposomal Anthracyclines
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
Abdominal Exploration Without Incisions
Diagnostic Transluminal Endoscopic Peritoneoscopy
Status: Archived
Ohio State University
mi
from
Columbus, OH
Abdominal Exploration Without Incisions
Diagnostic Transluminal Endoscopic Peritoneoscopy
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer
Phase I Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer
Status: Archived
Roger Williams Medical Center
mi
from
Providence, RI
Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer
Phase I Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer
Status: Archived
Updated: 1/1/1970
Roger Williams Medical Center
mi
from
Providence, RI
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Late Effects of Radiation Therapy and Natural History of Disease in Patients Previously Treated for Cancer at the National Institutes of Health
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Late Effects of Radiation Therapy and Natural History of Disease in Patients Previously Treated for Cancer at the National Institutes of Health
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Phase I, Open-Label, Dose-Escalation,Safety Study of the Combination of Sunitinib and Radiation Therapy for the Treatment of Patients With Cancer
Status: Archived
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Phase I, Open-Label, Dose-Escalation,Safety Study of the Combination of Sunitinib and Radiation Therapy for the Treatment of Patients With Cancer
Status: Archived
Updated: 1/1/1970
Thomas Jefferson Hospital
mi
from
Philadelphia, PA
Effectiveness of Protected Environment Rooms for AML and MDS
Effectiveness of HEPA-Filtered Rooms ("Protected Environment") to Prevent Morbidity and Mortality in Patients Age >/ = 60 Receiving Lower Intensity ("Targeted") Therapy for Untreated AML and High-Risk Myelodysplasia (MDS)
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Effectiveness of Protected Environment Rooms for AML and MDS
Effectiveness of HEPA-Filtered Rooms ("Protected Environment") to Prevent Morbidity and Mortality in Patients Age >/ = 60 Receiving Lower Intensity ("Targeted") Therapy for Untreated AML and High-Risk Myelodysplasia (MDS)
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Arvada, CO
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arvada, CO
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Atlanta, GA
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Atlanta, GA
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Bloomingdale, IL
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bloomingdale, IL
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Avon, IN
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Avon, IN
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Baltimore, MD
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Baltimore, MD
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Maine Research Associates
mi
from
Auburn, ME
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Maine Research Associates
mi
from
Auburn, ME
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Incline Village, NV
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Incline Village, NV
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Clifton, NJ
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Clifton, NJ
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Asheville, NC
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Asheville, NC
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Norman, OK
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Norman, OK
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Anderson, SC
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Anderson, SC
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
Urology Database for Outcomes Research
Urology Database for Outcomes Research
Status: Archived
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
Urology Database for Outcomes Research
Urology Database for Outcomes Research
Status: Archived
Updated: 1/1/1970
Wiiliam Beaumont Hospital
mi
from
Royal oak, MI
Education Sessions for Young Relative Stem Cell Donors
Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Education Sessions for Young Relative Stem Cell Donors
Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Study of Patients With Cancer or Precancerous Conditions
Treatment of Children With Cancer
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Study of Patients With Cancer or Precancerous Conditions
Treatment of Children With Cancer
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD